US Delisting Risk Hits I-Mab Hard, Bilateral Agreement Needed?
Switching Auditors Not Ultimate Solution
Executive Summary
It started with the risk of delisting from US stock markets over auditing requirements, but there are other underlying risks for Chinese bioventures that ultimately only some form of bilateral governmental agreement may need to address, but this may be increasingly hard to reach.
You may also be interested in...
China Planning To Ban Gene Editing Technology Exports
Beijing’s latest proposal to ban gene editing is viewed as a direct response to Washington’s tightening grip over the transfer of US technology to China.
Chinese Balloon Affair To Blow Up US Health Collaboration?
The latest surveillance balloon downing could torpedo improving bilateral health collaboration between China and the US at a time when warming ties are crucial to solving a flurry of gridlocks.
Chinese Balloon Affair To Blow Up US Health Collaboration?
The latest surveillance balloon downing could torpedo improving bilateral health collaboration between China and the US at a time when warming ties are crucial to solving a flurry of gridlocks.